DS-1 (drug)

DS-1 is a drug from the imidazopyridine family, which is the first drug developed that acts as a GABA_A receptor positive allosteric modulator (PAM) selective for the α4β3δ subtype, which is not targeted by other GABA_A receptor PAMs such as the benzodiazepines or other nonbenzodiazepine drugs. Novel selective drugs such as DS-1 should prove useful in the study of this receptor subtype.[1]

DS-1

Identifiers
IUPAC name 4-chloro-N-(6,8-dibromo-2-thiophen-2-ylimidazo[1,2-a]pyridin-3-yl)benzamide
CAS Number	372497-52-4^Y
PubChem CID	979735
IUPHAR/BPS	4183
ChemSpider	849261^Y
CompTox Dashboard (EPA)	DTXSID60359667
ECHA InfoCard	100.209.966
Chemical and physical data
Formula	C18H10Br2ClN3OS
Molar mass	511.62 g·mol^−1
3D model (JSmol)	Interactive image
SMILES s4cccc4-c2nc1c(Br)cc(Br)cn1c2NC(=O)c(cc3)ccc3Cl
(verify)

See also

• Alpidem
• Saripidem
• Zolpidem

References

1. Wafford KA, van Niel MB, Ma QP, Horridge E, Herd MB, Peden DR, et al. (January 2009). "Novel compounds selectively enhance delta subunit containing GABA A receptors and increase tonic currents in thalamus". Neuropharmacology. 56 (1): 182–9. doi:10.1016/j.neuropharm.2008.08.004. PMID 18762200. S2CID 207224202.